Please assess the completion status of the following clinical trial:

Trial Title: Soy Protein/Effexor Hormone Therapy for Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic documentation of prostate cancer, any stage Life expectancy of \> nine months~* Prior or current androgen deprivation for treatment or control of prostate cancer to include:~* Bilateral Orchiectomy~* LHRH agonist (with or without antiandrogen therapy) ie: leuprolide (Lupron), goserelin (Zoladex), bicalutamide (Casodex), flutamide (Eulexin), or similar agents~* Chemotherapy~* Radiation (Patients may undergo concurrent radiation therapy to the prostate, prostate + seminal vesicles, and/or pelvis). Seed implants are allowed~* Participant report of hot flash frequency of an average of four or more per day, as defined by sweating, flushing, sensation of warmth, night sweats (Average of 28 per week)~* Hot flashes must be moderate or severe (See appendix A for hot flash definitions)~* Grade 2 (Moderate flashes) are warmer, produce obvious perspiration, and last 2 to 3 minutes~* Grade 3 (Severe flashes) causes profuse perspiration, generate intense heat, last longer and interfere with ongoing activity~* Age \>21~* No allergies to soy or dairy products~* No current use of SSRIs, SNRI's, MAOIs, or Linezolide~* No uncontrolled hypertension (160/90) or greater than Class I American Heart Association functional capacity~* No history of mania, hypomania, bipolar disorder, or anorexia nervosa~* No history of seizures~* No history of hepatic dysfunction)~* Must have a telephone~* Signed protocol-specific Informed Consent~* Participants consuming soy foods or soy based supplements must continue on a stable regimen during study participation~* Patients should maintain same treatment and medications for prostate cancer throughout entire study.~* No change in treatment for 2 weeks prior to registration.~* Current use of medications and herbal supplements for hot flashes are allowed if on a stable regimen throughout the entire study. (Does not include anti-depressants)~Exclusion Criteria:~* Anticipated changes in prostate cancer treatment plan (i.e., hormonal manipulation, changes in chemotherapy)~* Concurrent antidepressant therapy~* History of intolerance to venlafaxine~* Recent (within 14 days) use of venlafaxine (Effexor XRTM), monoamine oxidase inhibitor, SSRI (selective serotonin reuptake inhibitor), or SNRI (selective norepinephrine reuptake inhibitor)~* History of seizure disorder

- Gender: MALE
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I - Placebo (Type: ACTIVE_COMPARATOR): Patients receive oral placebo pill and oral placebo powder once daily.
- Arm II - Soy (Type: ACTIVE_COMPARATOR): Patients receive oral placebo pill and oral soy protein/isoflavones powder once daily.
- Arm III - Venlafaxine (Type: EXPERIMENTAL): Patients receive oral Venlafaxine pill and placebo powder once daily.
- Arm IV - Soy + Venlafaxine (Type: PLACEBO_COMPARATOR): Patients receive oral Venlafaxine pill and soy protein/isoflavones powder once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy